Sionna Therapeutics Presents Preclinical Data on CF Treatments in Milan
Sionna Therapeutics has unveiled its preclinical research on cystic fibrosis (CF) treatment candidates during the European Cystic Fibrosis Society’s conference in Milan.
Conference Highlights
Sionna Therapeutics, Inc. shared that it will present preclinical data on two new treatment candidates, SION-451 and SION-719, from June 4-7, 2025, at the European Cystic Fibrosis Society (ECFS) conference. The presentation will detail how these NBD1 stabilizers may work alongside CFTR modulators, including galicaftor and SION-109, to effectively restore CFTR protein functionality in patients with the ΔF508 mutation. The session is scheduled for June 6, 2025, highlighting Sionna’s commitment to advancing innovative treatments for CF. Further insights will be available on Sionna’s website following the conference.
Potential Benefits
- The upcoming presentation promises important preclinical data that may herald advancements in the treatment of cystic fibrosis.
- The collaboration with various CFTR modulators signals a robust research and development agenda at Sionna Therapeutics.
- By targeting the major genetic mutation F508del, the company aims to significantly enhance the care and quality of life for CF patients.
Potential Concerns
- Currently, the press release does not contain new positive clinical trial data, which could raise questions about the efficacy and development of their therapies.
- No safety or efficacy details of the candidates were disclosed, leading to uncertainties regarding their market viability.
- Focusing on preclinical data rather than clinical trial outcomes may indicate that Sionna is still several steps away from regulatory approval.
FAQs
What is Sionna Therapeutics’ mission?
Sionna Therapeutics seeks to transform cystic fibrosis treatment by developing new medicines that restore normal CFTR protein function.
When is the European Cystic Fibrosis Conference scheduled?
The event will take place from June 4-7, 2025, in Milan, Italy.
What will be discussed during the oral presentation at the conference?
The focus will be on preclinical data concerning the use of NBD1 stabilizers in combination with CFTR modulators for cystic fibrosis treatment.
Who will present the findings?
Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President of Discovery Research at Sionna, will lead the presentation.
Where can I find more information about Sionna’s science presentations?
Details will be provided on the “Scientific Presentations” section of Sionna’s website on the day of the event.
$SION Insider Trading Activity
In the past six months, insiders have executed trades on $SION stock seven times, all involving purchases and no sales. Here’s a summary of these transactions:
- CAPITAL MANAGEMENT, L.P. RA purchased 1,125,000 shares for an estimated $20,250,000.
- GP A, LLC TPG acquired 1,125,000 shares for an estimated $20,250,000.
- ADVISORS LLC ORBIMED bought 550,000 shares for about $9,900,000.
- PETER A. THOMPSON purchased 550,000 shares for approximately $9,900,000.
- BRUCE BOOTH acquired 60,000 shares for an estimated $1,080,000.
- VENTURE FUND XI, L.P. ATLAS bought 60,000 shares for roughly $1,080,000.
Full Release
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a biopharmaceutical company focused on revolutionizing cystic fibrosis treatments, has announced the presentation of preclinical data that examines combinations of its nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary CFTR modulators, galicaftor (SION-2222) and SION-109. This will be featured in an oral presentation at the 48th European Cystic Fibrosis Conference from June 4-7, 2025, in Milan, Italy.
Details for the oral presentation include:
Abstract Title: Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ΔF508-CFTR
Abstract Number: WS19.01
Presenting Author: Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President, Discovery Research, Sionna
Session Title: WS19 – Upstream/downstream: new therapies for people with cystic fibrosis
Date and Time: Friday, June 6, 2025, from 5:00-5:15 p.m. CET / 11:00-11:15 a.m. ET
The presentation will be available on Sionna’s website under the “Scientific Presentations” section on the event day at here.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage company dedicated to innovating treatments for cystic fibrosis through the development of new medicines aimed at normalizing CFTR protein function. Their goal is to restore CFTR function and significantly enhance clinical outcomes and quality of life for individuals with CF by addressing the defects associated with the F508del genetic mutation.
Media Contact
Adam Daley
CG Life
212.253.8881
Investor Contact
Juliet Labadorf
